Safety of gadoterate meglumine in children younger than 2  years of age

ConclusionNo patient experienced adverse events directly related to gadoterate meglumine. Only two adverse events were reported to have occurred in the initial 2  h after the exam, while the rest were reported on the 24-h follow-up call. The higher reported rate of adverse events in this study may be related to concomitant sedation/anesthesia as well as to overreporting from parents on the 24-h follow-up questionnaire. The study confirms a good safety profi le for gadoterate meglumine in this very sensitive population.
Source: Pediatric Radiology - Category: Radiology Source Type: research